linjc16/ctgov huggingface dataset:
Handwriting Analysis in Movement Disorders

Study Overview
=================
Brief Summary
-----------------
Handwriting is a complex cognitive prowess that deteriorates in patients affected by neurodegenerative diseases, including movement disorders. More in detail, patients with Parkinson's disease (PD) may manifest prominent handwriting abnormalities which have been collectively identified as parkinsonian micrographia. MIcrographia may manifest at the onset of the disease and then worsens progressively with time. Previous techniques released to investigate micrographia in PD relied on perceptual analysis of simple tasks or were based on expensive technological tools, including tablets. However, handwriting can be promptly collected in an ecological scenario, through safe, cheap, and largely available tools. Also, the objective handwriting analysis through artificial intelligence would represent an innovative strategy even superior to previous techniques, since it allows for the analysis of large amounts of data. In this experimental project, the investigators apply a specific machine learning algorithm to analyze handwriting samples recorded in healthy controls and PD patients. The study aims to verify whether the technique proposed by the investigators would be able to detect parkinsonian micrographia objectively, monitor the evolution of handwriting abnormalities and assess the symptomatic improvement of handwriting following L-Dopa administration in PD patients.

Official Title
-----------------
Advanced Machine Learning Analysis of Handwriting in Patients With Movement Disorders

Conditions
-----------------
Movement Disorders, Parkinson Disease, Writing Disorder

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy conditions clinical diagnosis of Parkinson's disease Exclusion Criteria: cognitive decline

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Healthy Subjects<br>Collection of handwriting samples | |
| Patients with Parkinson's disease<br>Collection of handwriting samples | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Stroke size of handwriting characters | height of single letters | through study completion, an average of 1 year |
Study of Professional and Individual Factors of Covi-19 and Impact on Return to Work

Study Overview
=================
Brief Summary
-----------------
Started on January 9, 2020 with the announcement of the discovery of a new SARS-CoV-2 coronavirus, the Covid-19 pandemic is responsible as of June 21, 2020 for 160,377 confirmed cases in France, 29,640 deaths and 9,823 hospitalizations. The Grand Est region is one of the regions in France that was most precociously and strongly affected by the epidemic, in particular the Strasbourg University Hospital. Faced with the heavy use of the healthcare system, hospital staff of all categories are an essential resource to be preserved. Several studies have shown the significant impact of Covid-19 on doctors and caregivers. In order to better protect these personnel and avoid contamination that could be harmful to their health but also because of the consequences in terms of staff, it is necessary to better understand the risk factors for transmission of this infection, the means of protection, the evolution of the disease and the determinants of the return to work. Few studies have explored on such a large workforce and in detail the professional risk factors for developing Covid-19 within different groups of hospital professionals including also non-caregivers and the evolution when returning to work in an outpatient population.

Official Title
-----------------
SARS-COV-2 Infection Among Hospital Staff: Study of Professional and Individual Factors of Covi-19 and Impact on Return to Work

Conditions
-----------------
COVID-19

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Major subject (≥18 years old) Professionals from the University Hospitals of Strasbourg (HUS) Professionals who had been working at the HUS at the time of the diagnosis of SARS CoV-2 infection. Subject having not expressed, after being informed, opposition to the reuse of their data for research purposes Exclusion criteria: - Subject who expressed their opposition to participating in the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| positive RT-PCR test | The presence of SARS CoV 2 infection is assessed by a positive RT-PCR test | one week after infection with Covid-19 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COVID-19, SARS-COV-2
The Effect of an Exercise Program on the Health-quality of Life (HQL) in Older Adults

Study Overview
=================
Brief Summary
-----------------
The present study aimed to investigate the effect of exercise program on health-quality of life (HQL) in older adults.

Detailed Description
-----------------
The questionnaire consisted of demographic data (such as age, gender, educational level, and employment) and the LEIPAD questionnaire used to measure HQL.

Official Title
-----------------
The Effect of an Exercise Program on the Health-quality of Life (HQL) in Older

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Other: An exercise program


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: sixty healthy adults volunteers over the age of 55 years Exclusion Criteria: neurological disorder acute heart impairment unstable chronic illness severe musculo-skeletal impairment

Ages Eligible for Study
-----------------
Minimum Age: 55 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized


Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: An exercise program|The study subjects were recruited among those who responded to advertisements in outpatient clinics|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Exercise
Irreversible Electroporation (NanoKnife) for the Treatment of Pancreatic Adenocarcinoma

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to evaluate the use of irreversible electroporation in the treatment of locally advanced cancers of the head of pancreas with vascular spread. This technique would allow to treat the unresectable part of the tumor to make it more accessible for a secondary surgery.

Official Title
-----------------
Intérêt de l'électroporation irréversible Dans le Traitement de l'adénocarcinome du pancréas

Conditions
-----------------
Pancreatic Adenocarcinoma, Interventional Imaging

Intervention / Treatment
-----------------
* Device: NanoKnife


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with histologically proven adenocarcinoma of the head of the pancreas (fine needle aspiration or biopsy) Pancreatic adenocarcinoma locally advanced on imaging at diagnosis Tumor of less than 7 cm in largest diameter No chemotherapy or abdominal radiotherapy within five years before the inclusion in the study Exclusion Criteria: Pancreatic adenocarcinoma of more than 7 cm of diameter or immediately operable on imaging data Patient with contraindication of NanoKnife use Patient with neurostimulator Epileptic patient or with a myocardial infarction lasting less than 2 months Presence of visceral or lymph node metastases or peritoneal carcinosis at the initial workup Patient who cannot be treated with muscle blockers (curare) Patient with a metallic stent or a medical device implanted near the area treated by electroporation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Electrodes<br>Electrodes | Device: NanoKnife<br>* The aim of the treatment is to sourround the tumour with two to six needles and to deliver a very high voltage current (3000 volts in 70 to 80 microseconds pulses) by a generator synchronized with an electrocardiogram.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| R0 resection rate | Assessment of the R0 resection (complete tumour removal with negative resection margins) rate of locally advanced pancreatic cancer treated by electroporation | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Locally advanced pancreatic carcinoma, Irreversible electroporation, Interventional radiology
Chinese Health Investigation of Nurse Aging

Study Overview
=================
Brief Summary
-----------------
A follow-up intervention for the climacteric symptoms of nurses in Peking

Detailed Description
-----------------
As we all know,hormone replacement therapy (HRT) is the main therapy to climacteric symptoms.But HRT has also some disadvantages including breast cancer,cardiovascular disease and so on, especially long period of HRT. It makes us to find the non-hormone therapy. So we want to investigate the exercise on the effect of climacteric symptoms.Doing exercise is helpful for avoiding and treating many disease,including climacteric symptoms.In our previous research,we found that playing exercise can treat moderate climacteric symptoms.

Conditions
-----------------
Lipid Depletion, Excessive Physical Exercise, Unspecified, Menopausal Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: they are nurse ,aged40-55, lived in peking ,who are among perimenopausal women. Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the number of KMI | KMI is the short of Kupperman index, which is a questionnaire that assesses the severity of women's climacteric symptoms. | up to 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| blood lipid | blood lipid is an index to measure the effect of exercise. | up to 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
climacteric symptoms ; nurse ;, intervention;follow-up
Phenotype/Genotype Correlation in a Family With Early Onset Osteoarthritis

Study Overview
=================
Brief Summary
-----------------
This study will investigate the genes responsible for osteoarthritis. Individuals with osteoarthritis known or suspected to be caused by a gene mutation (change) may be eligible for this study. Family members may also participate. Patients will talk with investigators who will explain the study and its possible implications for the patient and family and answer questions. The patient's medical records will be reviewed, a personal and family history will be taken, and a physical examination will be done. Two procedures may be done including blood sampling (which will be used for DNA (genetic) studies) and X-rays (to define osteoarthritis grade). If no known mutations responsible for osteoarthritis will be detected, participating family members will be interviewed by telephone about their personal and family health history and will have a blood sample drawn for DNA testing, and X-rays.

Detailed Description
-----------------
We will investigate the clinical manifestations and molecular genetic defects of human osteoarthritis. Families with osteoarthritis of known or suspected genetic basis will be enrolled. Individuals will undergo clinical assessment and genetic analyses for the purpose of: 1) definition and characterization of phenotype, 2) determination of the natural history of the disorder, and 3) genotype/phenotype correlation. Genetic linkage studies may be performed for disorders in which the genetic bases is not yet known.

Official Title
-----------------
Phenotype/Genotype Correlation in a Family With Early Onset Osteoarthritis: Contribution of Genetic in the Diagnosis and Early Management of Patients.

Conditions
-----------------
Osteoarthritis

Intervention / Treatment
-----------------
* Radiation: radiography (X-ray)
* Genetic: DNA sampling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Individuals (and family members) with early onset osteoarthritis according to the following definition: symptomatic OA before 50 years old no obvious causes of OA (IMC > 30, dysplasia,joint traumas) at least three OA locations Exclusion Criteria: Individuals younger than 18 years old.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Osteoarthritis<br> | Radiation: radiography (X-ray)<br> <br> Genetic: DNA sampling<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identification of new gene mutations associated with early onset of osteoarthritis using NGS (Next Generation Sequencing) | Clinical, genetic and imaging factors of osteoarthritis | time of inclusion = Day 0 |
The Role of microRNA-29b in the Oral Squamous Cell Carcinoma

Study Overview
=================
Brief Summary
-----------------
The Role of microRNA-29b in the Oral Squamous Cell Carcinoma

Detailed Description
-----------------
To find out if there is prognostic value which to the performance of microRNA-29b of oral cancer in Taiwan and provide some reference for future treatment. We anticipate to enroll 100 persons with oral cancer and collect the tissue which was stained for pathological sections over a 3 year period. We also collect the blood and saliva samples from patients and the results along with patient-specific information such as tumor phases, tumor size, lymph node metastasis, cancer metastasis, prognosis and betel nut chewing, smoking and drinking habits and other parameters are statistically analyzed.

Official Title
-----------------
The Role of microRNA-29b in the Oral Squamous Cell Carcinoma

Conditions
-----------------
Oral Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Cancer of the oral cavity. Exclusion Criteria: pregnant woman refuse the surgery

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Oral cancer<br>Subjects who suffer from oral cancer. Subjects must: Should have a blood exam (20ml/each time) before the surgery and 3 months after the surgery. In the case the disease recurs after the surgery, subjects need to receive the surgery again and take another blood exam before the surgery and 3 months after the surgery. Before the surgery site staff must: Collect subjects' saliva once a day (in the morning before breakfast) for 3 consecutive days. Collect a 0.5x0.5Cm2 tissue sample of the tumor during the surgery. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| microRNA-29b |  | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
microRNA-29b, Oral squamous cell carcinoma, migration, prognosis
Left Atrial Appendage Occlusion and Biomarker Evaluation

Study Overview
=================
Brief Summary
-----------------
Left Atrial Appendage Occlusion and Biomarker Evaluation (LABEL) is a single-center, prospective and observational study evaluating changes of the expression of biomarkers in eligible patients before and after percutaneous implantation of a left atrial appendage (LAA) occlusion device at mid-term follow-up.

Detailed Description
-----------------
This study will evaluate the changes of different types of biomarkers before and after successful percutaneous implantation of an LAA occlusion device. Biomarker evaluation will focus on blood derived biomarkers including neurohormones, proteins, cytokines, microRNAs and metabolomics.

Official Title
-----------------
Left Atrial Appendage Occlusion and Biomarker Evaluation

Conditions
-----------------
Stroke, Atrial Fibrillation, Bleeding

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: non valvular atrial fibrillation, that makes anticoagulation to prevent embolic stroke from the LAA contraindication for the therapy with oral anticoagulants: refusal to take oral anticoagulation HasBled-score more than 3 prior bleedings under oral anticoagulation Exclusion Criteria: under 18 years severely reduced left atrial function mechanical heart valve pulmonary embolism deep vein thrombosis myocardial infarction within the last 3 months electrical cardioversion within 30 days after potential occluder implantation atrial septum defect or interventional/surgical occlusion of ASD status after heart transplant symptomatic carotid artery stenosis transient ischemic attack (TIA) or stroke within last 30 days intracerebral bleeding within the last 2 months acute infection existing or planned pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Biomarker levels before successful LAA occlusion device implantation |  | 24 hours before intervention | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Biomarker levels after successful LAA occlusion device implantation |  | mid-term follow up at 6 months | 
| Changes of biomarker expression before and after device implantation over mid-term follow-up, depending of complete, incomplete occlusion, imaging data (transesophageal echocardiography, computed tomography) |  | mid-term follow up at 6 months |
GR Defect in Sputum Cells in COPD

Study Overview
=================
Brief Summary
-----------------
To investigate a possible mechanism of the GR defect in patients with severe COPD by studying the effect of dexamethasone (Dex) on GR-GRE binding, expression of inflammatory and anti-inflammatory factors such as IL-6, IL-8, MKP-1, GILZ, SLPI production in sputum cells

Official Title
-----------------
GR Defect in Sputum Cells in COPD

Conditions
-----------------
Chronic Obstructive Pulmonary Disease (COPD)

Intervention / Treatment
-----------------
* Procedure: Induced Sputum


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with moderate (stage II, GOLD) COPD or subjects who are healthy smokers or subjects who are non-smokers. Written informed consent Exclusion Criteria: Current upper respiratory tract infections Any significant disease or disorder (e.g. cardiovascular, pulmonary (other than asthma), gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic, malignant, psychiatric, major physical impairment) which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or may influence the results of the study, or the subjects ability to participate in the study Subjects not considered capable, as judged by the investigator, of following instructions of the study, e.g. because of a history of alcohol or drug abuse or any other reason

Ages Eligible for Study
-----------------
Minimum Age: 35 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Induced Sputum|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |